Biomark Diagnostics (FRA:20B) Cash per Share: €0.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:20B Biomark Diagnostics Inc FRA:20B
32 GF Score
Price €0.28
! 3 Warning Signs
View Full Analysis

What is Biomark Diagnostics Cash per Share?

Biomark Diagnostics FRA:20B 32 Cash per Share is €0.01 as of Jun. 2026. GuruFocus rates FRA:20B with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Biomark Diagnostics's Cash per Share for the quarter that ended in Jun. 2026 was €0.01.

Biomark Diagnostics  (FRA:20B) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Biomark Diagnostics Cash per Share Related Terms

Biomark Diagnostics Cash per Share Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics Cash per Share Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.02 0.01

Biomark Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
FRA:20B
32GF Score
Biomark Diagnostics Inc FRA:20B
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Biomark Diagnostics's Cash per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.6286926187027/105.09
=0.01

Biomark Diagnostics's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.48600207067339/106.48
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €0.01 mean?
Biomark Diagnostics (FRA:20B) has a Cash per Share of €0.01 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' Cash per Share too high?
Biomark Diagnostics' current Cash per Share is €0.01. Overall, Biomark Diagnostics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Cash per Share compare to TMO and DHR?
Biomark Diagnostics' Cash per Share of €0.01 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Medical Diagnostics & Research company?
A good Cash per Share depends on the Medical Diagnostics & Research industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Biomark Diagnostics and its competitors. Biomark Diagnostics's current Cash per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (FRA:20B) has a current Cash per Share of €0.01. The current Cash per Share is €0.01. Biomark Diagnostics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Biomark Diagnostics (FRA:20B), the current Cash per Share is €0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
32GF Score

Get the complete analysis for FRA:20B

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.28
Price